GlassScriptPhysician profile
Michael R Motta
NPI 1720037443
$4,951.91
in general payments reported to CMS, 2019-2025
26 companies · $176 in 2025
The $176 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,195 · 2020: $445 · 2021: $610 · 2022: $1,058 · 2023: $970 · 2024: $499 · 2025: $176.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,644.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,643.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,480.28 | 2019-2025 | Trelegy Ellipta, Nucala |
| Astrazeneca Pharmaceuticals LP | $884.08 | 2019-2024 | Breztri, Airsupra, Symbicort |
| Boehringer Ingelheim Pharmaceuticals, INC. | $501.67 | 2019-2024 | Ofev |
| Actelion Pharmaceuticals US, INC. | $368.60 | 2019-2025 | Opsumit |
| Electromed, INC. | $299.96 | 2019-2023 | Smartvest |
| Sunovion Pharmaceuticals INC. | $267.82 | 2019-2021 | |
| Philips North America LLC | $215.31 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $143.87 | 2019-2023 | Recarbrio, Zerbaxa, Dificid |
| Abbott Laboratories | $134.87 | 2023 | Thoratec Heartmate 3 Lvas Implant Kit |
| Mylan Specialty L.P. | $111.87 | 2019-2022 | |
| Baxter Healthcare | $74.80 | 2022-2023 | Hillrom - Life 2000 Ventilation System |
| Harmony Biosciences LLC | $56.80 | 2021-2023 | Wakix |
| Mallinckrodt Hospital Products INC. | $54.26 | 2023-2024 | Acthar |
| Abbvie INC. | $48.85 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $47.04 | 2019-2023 | Dupixent |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $46.76 | 2023-2025 | Arikayce |
| Teva Pharmaceuticals USA, INC. | $42.19 | 2021 | |
| Genzyme Corporation | $32.49 | 2023 | |
| Covis Pharma Gmbh | $20.51 | 2022 | |
| Gilead Sciences, INC. | $18.94 | 2021 | |
| Novartis Pharmaceuticals Corporation | $18.90 | 2019 | |
| Mayne Pharma Commercial LLC | $18.76 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $18.52 | 2022 | |
| Inogen, INC. | $18.20 | 2019 | |
| Shire North American Group INC | $13.32 | 2019 | |
| Nabriva Therapeutics, Plc | $13.24 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Motta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.